Negocie BioNTech BNTX

Venda
 Comprar

Gráfico BioNTech ao vivo

5m 15m 30m 1h 4h 1d 1w

Fundamentos do instrumento

Weekly Search
Weekly
Daily
Data Fechar Mudança Alteração (%): Abertura Max Min

BioNTech news

Tommy Yap 2025 Mar 04, 16:00

Week Ahead: U.S. Inflation Data and BoC Policy Rate in Focus

Forex Indices
Moderna Share Price
Georgy Istigechev 2024 Jan 03, 08:01

Moderna share price jumps as Oppenheimer upgrades stock

Shares
Pfizer shares sink as revenue prospects
Georgy Istigechev 2023 Dec 14, 05:13

Pfizer shares sink on lower COVID revenue prospects

Shares
shutterstock_1781525795.jpg
Zachariah Walker 2023 Feb 14, 09:11

5 Stocks to Fall in Love with this Valentines Day

2021 Aug 24, 08:05

Stocks make further gains as oil bounce carries on

Últimas notícias

Mostrar mais
Sophia Claire 2025 Sep 30, 01:20

Potential Government Shutdown Threatens Key US Economic Data Delays

Noah Lee 2025 Sep 29, 14:20

Trump's 100% Tariff on Foreign Films: Hollywood's Future at Stake?

Liam James 2025 Sep 29, 06:20

Buffett Indicator Hits Record High: Market Valuation Concerns

Ava Grace 2025 Sep 29, 04:20

US Allies in Asia Balk at Trump's Investment Demands: South Korea and Japan Reassess Pledges

Liam James 2025 Sep 29, 03:20

US Treasury Yields Navigate Fed Uncertainty, Government Shutdown Risk

Emma Rose 2025 Sep 29, 02:20

Netanyahu-Trump Meeting: A New Gaza Peace Plan on the Table

Ava Grace 2025 Sep 29, 01:20

Fed Chair Succession: Waller vs. Hassett - Economists' Wishes vs. Political Reality

Liam James 2025 Sep 28, 06:20

Trump Mocks Powell with AI Image Amidst Rate Cut Debate

Info

Spread

0.8226

Spread (%)

0.7833 %

Alavancagem

1:10

Juro overnight, Compra

-0.0597 %

Juro overnight, Venda

-0.0292 %

Moeda

USD

Horários de Negociação

Mercados fechados

Segunda-feira

13:31 - 19:59

Terça-feira

13:31-19:59

Quarta-feira

13:31-19:59

Quinta-feira

13:31-19:59

Sexta-feira

13:31-19:59

Análise e estatística

Abertura

---

Fechamento anterior

---

Alta/baixa em 52 semanas

--- – ---

Capitalização de mercado

25359661056

Ações em circulação

240398724

Data dos rendimentos (Próxima)

0000-00-00

Rendim Divid

2022-06-17

Data Ex-Dividendos

2022-06-02

Taxa anual futura de dividendos

0

Rendimento anual futuro de dividendos

0

EPS

-1.68

Saiba mais sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Instrumentos relacionados

Ativo
Venda
Comprar
Alteração (%):

Negociar agora

Negociar agora

Negociar agora

Negociar agora
Instrumentos relacionados

latest_education_articles

Mostrar mais
Trustpilot